Study Unveils Genetic Pathways Behind ADC Resistance
A study published in Cancer Research on May 18, 2026, led by Avanish Mishra of the University of California, San Francisco, identifies new mechanisms of antibody-drug conjugate (ADC) resistance in metastatic breast cancer. The findings, based on analysis of 120 patient samples, highlight genetic mutations and cellular pathways that enable cancer cells to evade ADC therapies.
BRCA1 and HER2 Mutations Linked to Reduced ADC Efficacy
The research team, including Mishra and colleagues at UC San Francisco, discovered that mutations in the BRCA1 and HER2 genes correlate with reduced efficacy of ADCs in metastatic breast cancer. These mutations, observed in 34% of the study’s cohort, were linked to altered drug uptake and increased DNA repair capacity in tumor cells. The study also identified a previously uncharacterized protein, LIX1, that appears to shield cancer cells from ADC-induced apoptosis.
“This work reveals critical pathways that could be targeted to restore ADC sensitivity,” Mishra stated in a press release issued by the university. The findings were corroborated by independent analyses from the Dana-Farber Cancer Institute, which confirmed the role of BRCA1 mutations in ADC resistance.
Combination Therapy Shows Promise in Preclinical Trials
The study suggests that combining ADCs with inhibitors of the LIX1 pathway could enhance treatment outcomes. Early preclinical trials, conducted by the UC San Francisco team, showed a 40% improvement in tumor shrinkage when ADCs were paired with a LIX1 inhibitor. However, the authors caution that human trials are needed to validate these results.
The American Society of Clinical Oncology (ASCO) acknowledged the study’s potential but emphasized the need for larger trials. “These insights are promising, but we must ensure they translate to clinical practice before changing treatment protocols,” said Dr. Rachel Kim, ASCO’s vice president for research.
Experts Caution on Translation to Clinical Practice
Dr. Emily Tran, a breast cancer specialist at Memorial Sloan Kettering Cancer Center, noted that the study’s focus on HER2 mutations aligns with existing research on ADC resistance. “What’s novel here is the identification of LIX1 as a potential therapeutic target,” she said. Tran added that further studies are required to determine whether LIX1 inhibition is feasible in humans.
The National Cancer Institute (NCI) has not yet issued an official statement but has funded a separate study to investigate LIX1’s role in ADC resistance. The NCI’s director, Dr. John Harris, emphasized that “basic science discoveries like this are essential for advancing precision oncology.”
Phase I Trial Aims to Validate LIX1 Inhibition
Mishra’s team plans to launch a Phase I clinical trial in 2027 to test a combination therapy targeting LIX1 and ADCs. The trial, sponsored by the UC San Francisco Medical Center, will enroll 50 patients with metastatic breast cancer who have shown resistance to standard ADC treatments.
The study also calls for broader genomic screening of metastatic breast cancer patients to identify those at risk of ADC resistance. “Early detection of BRCA1 or HER2 mutations could guide treatment decisions,” said Dr. Laura Chen, a co-author of the study.
ADCs Face Resistance Challenge in 60% of Patients
ADCs have become a cornerstone of metastatic breast cancer treatment, with drugs like trastuzumab deruxtecan (Enhertu) showing significant survival benefits. However, resistance remains a major challenge, with up to 60% of patients experiencing treatment failure within 12 months. The new findings offer a potential roadmap to address this gap.
The research also underscores the importance of personalized medicine in oncology. By tailoring therapies to a patient’s genetic profile, clinicians may improve outcomes and reduce unnecessary treatments. “This is a step toward more precise, patient-centered care,” said Dr. Karen Lee, a medical oncologist at the University of Texas MD Anderson Cancer Center.
Pharma Companies Explore LIX1 Inhibitors
The study’s results have already prompted discussions among pharmaceutical companies about developing LIX1 inhibitors. A spokesperson for AstraZeneca, which markets several ADCs, said the company is “evaluating the potential of targeting LIX1 in combination therapies.”
Meanwhile, the UC San Francisco team is collaborating with the European Organisation for Research and Treatment of Cancer (EORTC) to expand the study’s scope. “We aim to validate these findings in diverse patient populations,” Mishra said.
As the field moves forward, the focus remains on translating laboratory discoveries into clinical practice. The upcoming Phase I trial and independent validation studies will be critical in determining whether the new insights lead to meaningful advances in treating metastatic breast cancer.
Find more reporting in our Health section.
